SMR9 Antibody
Description
Possible Nomenclature Misalignment
The term "SMR9" does not align with established antibody naming conventions (e.g., WHO’s International Nonproprietary Names [INN]) or known therapeutic candidates. Potential overlaps include:
-
Anti-Sm antibodies: Well-characterized autoantibodies targeting Smith antigens in systemic lupus erythematosus (SLE). These are distinct from "SMR9" but share partial terminology .
-
TLR9-related pathways: Toll-like receptor 9 (TLR9) is implicated in autoimmune responses (e.g., anti-DNA/anti-Sm antibody production), but no antibody named "SMR9" targeting TLR9 is documented .
-
SARS-CoV-2 antibodies: Monoclonal antibodies like S2X259 or REGN10933 target conserved viral epitopes but bear no nomenclature similarity .
Anti-Sm Antibodies
SARS-CoV-2 Neutralizing Antibodies
| Antibody | Target Epitope | Key Attributes | Clinical Status |
|---|---|---|---|
| S2X259 | Conserved RBD site II | Neutralizes sarbecoviruses, including Omicron | Preclinical/Phase I |
| REGN10933 | SARS-CoV-2 RBD | Part of REGEN-COV cocktail; blocks ACE2 binding | Approved (EUA) |
| S309 | Non-RBM RBD | Broad activity against coronaviruses | Phase II/III |
Recommendations for Clarification
-
Verify Nomenclature: Confirm whether "SMR9" refers to:
-
A typo (e.g., "S2M9," "SMR-9," or "SM-R9").
-
A proprietary candidate not yet published or registered in public databases.
-
-
Explore Context: If "SMR9" relates to:
-
Consult Specialized Databases:
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
Here’s a structured collection of FAQs for researchers working with SMR9 antibodies, based on scientific rigor and methodological challenges observed in the provided research materials:
How to validate SMR9 antibody specificity in experimental models?
Methodological steps include:
-
Knockout controls: Use genetic knock-out cell lines or tissues lacking the target antigen to confirm absence of non-specific binding .
-
Multi-platform validation: Combine Western blot (reduced/denatured samples), immunofluorescence (native conformation), and ELISA (quantitative epitope recognition) .
-
Cross-reactivity screening: Test against homologous proteins or isoforms using antigen-spiked lysates .
What experimental designs optimize SMR9 antibody performance in immunohistochemistry?
-
Fixation compatibility: For formalin-fixed paraffin-embedded (FFPE) tissues, validate antigen retrieval methods (e.g., citrate buffer vs. enzymatic digestion) .
-
Concentration titration: Use a checkerboard assay to balance signal-to-noise ratios (e.g., 0.1–10 μg/mL) .
-
Isotype controls: Include species-matched non-specific IgG to identify background staining .
How to address batch-to-batch variability in SMR9 antibody production?
-
Recombinant antibodies: Prioritize clones with sequenced variable regions to ensure reproducibility .
-
Lot-specific validation: Re-test critical applications (e.g., flow cytometry, IP-MS) with each new batch .
-
Epitope mapping: Confirm consistency in recognized regions via peptide arrays or hydrogen-deuterium exchange mass spectrometry .
What computational approaches predict SMR9 antibody-epitope interactions?
-
Energy-based modeling: Optimize binding profiles by minimizing interaction energies for target epitopes while maximizing rejection of off-target ligands .
-
Phage display data integration: Train machine learning models on deep mutational scanning datasets to infer paratope-epitope compatibility .
-
In silico cross-reactivity screening: Use structural homology models (e.g., AlphaFold) to predict off-target binding risks .
How to resolve contradictions in SMR9 antibody data across studies?
What in vivo models best replicate human conditions for SMR9 antibody studies?
-
Transgenic knock-in models: Engineer humanized epitopes in murine systems to mirror human immune responses .
-
Disease-specific cohorts: Use patient-derived xenografts or induced pluripotent stem cell (iPSC) models for autoimmune or neurodegenerative contexts .
-
Dose-response calibration: Titrate antibody administration to match physiological exposure levels observed in human sera .
Methodological Insights from Recent Studies
Critical Data Interpretation Guidelines
-
Discordant ELISA vs. Western blot results: May indicate conformational vs. linear epitope recognition; validate with native PAGE or SPR .
-
Unexpected tissue staining patterns: Perform antibody blocking assays with recombinant antigens or competing peptides .
-
Inconsistent inter-laboratory data: Adopt standardized validation pipelines (e.g., CRISPR-Cas9 knockouts + multi-platform assays) .
